2022年度胰腺癌研究及诊疗新进展

王旭; 程合; 刘辰; 虞先濬

doi:10.19401/j.cnki.1007-3639.2023.01.001

您当前的位置：

首页 >

文章列表页 >

2022年度胰腺癌研究及诊疗新进展

专家述评 | 更新时间：2025-12-31

- 2022年度胰腺癌研究及诊疗新进展
- New progress in basic research, clinical diagnosis and treatment of pancreatic cancer in 2022
- 中国癌症杂志 2023年33卷第1期页码：1-13
- 作者机构：
  
  复旦大学附属肿瘤医院胰腺外科，复旦大学上海医学院肿瘤学系，复旦大学胰腺肿瘤研究所，上海市胰腺肿瘤研究所，上海 200032
- 作者简介：
  
  [ "王旭（ORCID: 0000-0001-6920-0375），博士，副研究员。" ]
  [ "虞先濬，主任医师，二级教授，外科学和肿瘤学双科博士研究生导师，现任复旦大学附属肿瘤医院副院长、上海市胰腺肿瘤研究所所长、复旦大学胰腺肿瘤研究所所长、中国抗癌协会胰腺癌专业委员会主任委员。长期从事胰腺肿瘤外科基础和临床转化研究。获得国家杰出青年科学基金、全国五一劳动奖章，入选科技部“中青年科技创新领军人才”、国家百千万人才工程“有突出贡献中青年专家”，享受国务院政府特殊津贴，被评为上海市科技精英、上海市领军人才、上海工匠、上海市优秀学术带头人。主持国家自然科学基金中德国际重点合作项目1项、区域合作重点项目1项、面上项目3项，省部级项目12项。以通信作者在Journal of Clinical Oncology、Gut、Annals of Surgery、Cell Research、Autophagy、Clinical Cancer Research、Cancer Research等国际权威SCI收录期刊上发表论文200余篇，获得国家实用新型专利5项。作为第一完成人获得中国抗癌协会科技奖一等奖、上海医学科技奖一等奖、上海市职工优秀创新成果奖一等奖。" ]
- 基金信息：
  
  国家自然科学基金(82172884);国家自然科学基金(82072693);国家自然科学基金(81902417);国家自然科学基金(U21A20374);上海市教委科技创新项目(2019-01-07-00-07-E00057);上海市科学技术重大项目(21JC1401500);上海市医院发展中心临床与科技创新项目(SHDC12018109);上海市医院发展中心临床与科技创新项目(SHDC2020CR1006A);国家重点研发计划(2020YFA0803202)
- DOI：10.19401/j.cnki.1007-3639.2023.01.001
  中图分类号： R735.9
- 收稿：2022-12-30，
  
  修回：2023-01-13，
  
  纸质出版：2023-01-30
- 稿件说明：
移动端阅览
王旭, 程合, 刘辰, 等. 2022年度胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2023,33(1):1-13.

Xu WANG, He CHENG, Chen LIU, et al. New progress in basic research, clinical diagnosis and treatment of pancreatic cancer in 2022[J]. China Oncology, 2023, 33(1): 1-13.
王旭, 程合, 刘辰, 等. 2022年度胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2023,33(1):1-13. DOI： 10.19401/j.cnki.1007-3639.2023.01.001.

Xu WANG, He CHENG, Chen LIU, et al. New progress in basic research, clinical diagnosis and treatment of pancreatic cancer in 2022[J]. China Oncology, 2023, 33(1): 1-13. DOI： 10.19401/j.cnki.1007-3639.2023.01.001.

摘要

胰腺癌是中国致死人数排名第六的恶性肿瘤，其恶性程度高，早期病情隐匿，超过80%的患者在就诊时已进展为晚期，错失手术切除治愈的机会；而成功接受了手术治疗的胰腺癌患者，也极易发生转移，5年生存率仅为15% ~ 20%。不同于其他癌种，胰腺癌的放化疗及免疫治疗效率均较低，分子分型和精准治疗技术的研究也相对落后，急需临床医疗资源的投入和优质科研成果的转化，以改善患者预后。2022年是胰腺癌转化研究领域厚积薄发的一年，见证了第1个靶向KRAS

G12D

的小分子药物的诞生和个性化T细胞受体工程化T（T-cell receptor engineered T，TCR-T）细胞治疗技术的临床应用，在胰腺癌发病因素、分子机制、代谢、免疫微环境等基础领域，以及早期诊断、手术治疗、药物治疗、免疫治疗等临床领域也各自取得了新突破。本文对2022年胰腺癌研究和诊疗领域的最新进展进行综述。

Abstract

Pancreatic cancer is the sixth leading cause of cancer-related death in China. It is characterized by high malignancy and concealment at early stages. More than 80% of patients have progressed to advanced stages at the time of diagnosis

and missed the opportunity of surgical resection. Pancreatic cancer patients who have successfully received surgical resection are at a high risk of metastasis

and the 5-year survival rate is only 15%-20%. Unlike other types of cancer

radiotherapy

chemotherapy and immunotherapy do not work well for pancreatic cancer

and the research in molecular subtyping and precision medical therapy technology is also slow. It is an urgent need to devote more clinical medical resources and transfer high-quality scientific research achievements to improve the prognosis of patients. The year 2022 is a year

of profound accumulation in the field of translational pancreatic cancer research

witnessing the generation of the first small-molecule drug targeting KRAS

G12D

and the clinical application of personalized T-cell receptor engineered T (TCR-T) cell therapy

as well as other advances in basic fields such as pathogenesis

molecular mechanism

metabolic immune microenvironment

and clinical fields such as early diagnosis

surgical treatment

radiation therapy

chemotherapy and immunotherapy. Here we reviewed the latest progress in research

diagnosis and treatment of pancreatic cancer in 2022.

关键词

Keywords

references

SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 . DOI: 10.3322/caac.21660 http://doi.org/10.3322/caac.21660 https://onlinelibrary.wiley.com/doi/10.3322/caac.21660 https://onlinelibrary.wiley.com/doi/10.3322/caac.21660

WILD C P , WEIDERPASS E , STEWART B W . World cancer report: cancer research for cancer prevention [M ] . Lyon : IARC Publications , 2020 .

SIEGEL R L , MILLER K D , FUCHS H E , et al . Cancer statistics, 2022 [J ] . CA Cancer J Clin , 2022 . 72 ( 1 ): 7 - 33 . DOI: 10.3322/caac.21708 http://doi.org/10.3322/caac.21708 https://onlinelibrary.wiley.com/doi/10.3322/caac.21708 https://onlinelibrary.wiley.com/doi/10.3322/caac.21708

XIA C F , DONG X S , LI H , et al . Cancer statistics in China and United States, 2022: profiles, trends, and determinants [J ] . Chin Med J (Engl) , 2022 , 135 ( 5 ): 584 - 590 .

IRFAN A , FANG H A , AWAD S , et al . Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? [J ] . Am J Surg , 2022 , 224 ( 3 ): 955 - 958 . DOI: 10.1016/j.amjsurg.2022.04.004 http://doi.org/10.1016/j.amjsurg.2022.04.004

ARJANI S , SAINT-MAURICE P F , JULIÁN-SERRANO S , et al . Body mass index trajectories across the adult life course and pancreatic cancer risk [J ] . JNCI Cancer Spectr , 2022 , 6 ( 6 ): pkac066 . DOI: 10.1093/jncics/pkac066 http://doi.org/10.1093/jncics/pkac066 https://academic.oup.com/jncics/article/doi/10.1093/jncics/pkac066/6762867 https://academic.oup.com/jncics/article/doi/10.1093/jncics/pkac066/6762867

SHARMA S , TAPPER W J , COLLINS A , et al . Predicting pancreatic cancer in the UK biobank cohort using polygenic risk scores and diabetes mellitus [J ] . Gastroenterology , 2022 , 162 ( 6 ): 1665 - 1674.e2 . DOI: 10.1053/j.gastro.2022.01.016 http://doi.org/10.1053/j.gastro.2022.01.016 https://linkinghub.elsevier.com/retrieve/pii/S0016508522000324 https://linkinghub.elsevier.com/retrieve/pii/S0016508522000324

WANG L , SCOTT F I , BOURSI B , et al . Cost-effectiveness of a risk-tailored pancreatic cancer early detection strategy among patients with new-onset diabetes [J ] . Clin Gastroenterol Hepatol , 2022 , 20 ( 9 ): 1997 - 2004.e7 . DOI: 10.1016/j.cgh.2021.10.037 http://doi.org/10.1016/j.cgh.2021.10.037 https://linkinghub.elsevier.com/retrieve/pii/S1542356521011502 https://linkinghub.elsevier.com/retrieve/pii/S1542356521011502

JULIÁN-SERRANO S , REEDY J , ROBIEN K , et al . Adherence to 5 diet quality indices and pancreatic cancer risk in a large US prospective cohort [J ] . Am J Epidemiol , 2022 , 191 ( 9 ): 1584 - 1600 . DOI: 10.1093/aje/kwac082 http://doi.org/10.1093/aje/kwac082 https://academic.oup.com/aje/article/191/9/1584/6574278 https://academic.oup.com/aje/article/191/9/1584/6574278

MUNIGALA S , SUBRAMANIAM D S , SUBRAMANIAM D P , et al . Incidence and risk of pancreatic cancer in patients with a new diagnosis of chronic pancreatitis [J ] . Dig Dis Sci , 2022 , 67 ( 2 ): 708 - 715 . DOI: 10.1007/s10620-021-06886-7 http://doi.org/10.1007/s10620-021-06886-7 https://doi.org/10.1007/s10620-021-06886-7 https://doi.org/10.1007/s10620-021-06886-7

MUNIGALA S , ALMASKEEN S , SUBRAMANIAM D S , et al . Acute pancreatitis recurrences augment long-term pancreatic cancer risk [J ] . Am J Gastroenterol , 2022 . [Online ahead of print ]

MAHAJAN U M , OEHRLE B , SIRTL S , et al . Independent validation and assay standardization of improved metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis [J ] . Gastroenterology , 2022 , 163 ( 5 ): 1407 - 1422 . DOI: 10.1053/j.gastro.2022.07.047 http://doi.org/10.1053/j.gastro.2022.07.047

CHEN W S , CHEN Q L , PARKER R A , et al . Risk prediction of pancreatic cancer in patients with abnormal morphologic findings related to chronic pancreatitis: a machine learning approach [J ] . Gastro Hep Adv , 2022 , 1 ( 6 ): 1014 - 1026 . DOI: 10.1016/j.gastha.2022.06.008 http://doi.org/10.1016/j.gastha.2022.06.008 https://linkinghub.elsevier.com/retrieve/pii/S2772572322001030 https://linkinghub.elsevier.com/retrieve/pii/S2772572322001030

POLLINI T , ADSAY V , CAPURSO G , et al . The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms [J ] . Lancet Gastroenterol Hepatol , 2022 , 7 ( 12 ): 1141 - 1150 . DOI: 10.1016/S2468-1253(22)00235-7 http://doi.org/10.1016/S2468-1253(22)00235-7 https://linkinghub.elsevier.com/retrieve/pii/S2468125322002357 https://linkinghub.elsevier.com/retrieve/pii/S2468125322002357

HERNANDEZ S , PARRA E R , URAOKA N , et al . Diminished immune surveillance during histologic progression of intraductal papillary mucinous neoplasms offers a therapeutic opportunity for cancer interception [J ] . Clin Cancer Res , 28 ( 9 ): 1938 - 1947 . DOI: 10.1158/1078-0432.CCR-21-2585 http://doi.org/10.1158/1078-0432.CCR-21-2585 https://aacrjournals.org/clincancerres/article/28/9/1938/694447/Diminished-Immune-Surveillance-during-Histologic https://aacrjournals.org/clincancerres/article/28/9/1938/694447/Diminished-Immune-Surveillance-during-Histologic

LIFFERS S T , GODFREY L , FROHN L , et al . Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype [J ] . Gut , 2022 : gutjnl-gu 2021 - 326550 .

FELIX K , HONDA K , NAGASHIMA K , et al . Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms [J ] . Int J Cancer , 2022 , 150 ( 5 ): 881 - 894 . DOI: 10.1002/ijc.33875 http://doi.org/10.1002/ijc.33875 https://onlinelibrary.wiley.com/doi/10.1002/ijc.33875 https://onlinelibrary.wiley.com/doi/10.1002/ijc.33875

YAMAGUCHI A , TAZUMA S , TAMARU Y , et al . Long-standing diabetes mellitus increases concomitant pancreatic cancer risk in patients with intraductal papillary mucinous neoplasms [J ] . BMC Gastroenterol , 2022 , 22 ( 1 ): 529 . DOI: 10.1186/s12876-022-02564-8 http://doi.org/10.1186/s12876-022-02564-8

PEDUZZI G , ARCHIBUGI L , KATZKE V , et al . Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women [J ] . Sci Rep , 2022 , 12 ( 1 ): 18100 . DOI: 10.1038/s41598-022-22973-9 http://doi.org/10.1038/s41598-022-22973-9

CAO L W , HUANG C , CUI ZHOU D , et al . Proteogenomic characterization of pancreatic ductal adenocarcinoma [J ] . Cell , 2021 , 184 ( 19 ): 5031 - 5052.e26 . DOI: 10.1016/j.cell.2021.08.023 http://doi.org/10.1016/j.cell.2021.08.023

LEIDNER R , SANJUAN SILVA N , HUANG H Y , et al . Neoantigen T-cell receptor gene therapy in pancreatic cancer [J ] . N Engl J Med , 2022 , 386 ( 22 ): 2112 - 2119 . DOI: 10.1056/NEJMoa2119662 http://doi.org/10.1056/NEJMoa2119662 http://www.nejm.org/doi/10.1056/NEJMoa2119662 http://www.nejm.org/doi/10.1056/NEJMoa2119662

ASTIAZARAN-SYMONDS E , KIM J , HALEY J S , et al . A genome-first approach to estimate prevalence of germline pathogenic variants and risk of pancreatic cancer in select cancer susceptibility genes [J ] . Cancers , 2022 , 14 ( 13 ): 3257 . DOI: 10.3390/cancers14133257 http://doi.org/10.3390/cancers14133257 https://www.mdpi.com/2072-6694/14/13/3257 https://www.mdpi.com/2072-6694/14/13/3257

GARDINER A , KIDD J , ELIAS M C , et al . Pancreatic ductal carcinoma risk associated with hereditary cancer-risk genes [J ] . J Natl Cancer Inst , 2022 , 114 ( 7 ): 996 - 1002 . DOI: 10.1093/jnci/djac069 http://doi.org/10.1093/jnci/djac069 https://academic.oup.com/jnci/article/114/7/996/6571816 https://academic.oup.com/jnci/article/114/7/996/6571816

GIACCHERINI M , FARINELLA R , GENTILUOMO M , et al . Association between a polymorphic variant in the CDKN 2 B - AS 1/ ANRIL gene and pancreatic cancer risk [J ] . Int J Cancer , 2022 . [Online ahead of print ]

SARDARZADEH N , KHOJASTEH-LEYLAKOOHI F , DAMAVANDI S , et al . Association of a genetic variant in the cyclin-dependent kinase inhibitor 2B with risk of pancreatic cancer [J ] . Rep Biochem Mol Biol , 2022 , 11 ( 2 ): 336 - 343 .

GIACCHERINI M , GENTILUOMO M , ARCIDIACONO P G , et al . A polymorphic variant in telomere maintenance is associated with worrisome features and high-risk stigmata development in IPMNs [J ] . Carcinogenesis , 2022 , 43 ( 8 ): 728 - 735 . DOI: 10.1093/carcin/bgac051 http://doi.org/10.1093/carcin/bgac051

RAMAKRISHNAN G , PARAJULI P , SINGH P , et al . NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma [J ] . Cell Rep , 2022 , 41 ( 6 ): 111623 . DOI: 10.1016/j.celrep.2022.111623 http://doi.org/10.1016/j.celrep.2022.111623 https://linkinghub.elsevier.com/retrieve/pii/S2211124722014942 https://linkinghub.elsevier.com/retrieve/pii/S2211124722014942

TIAN J B , CHEN C , RAO M L , et al . Aberrant RNA splicing is a primary link between genetic variation and pancreatic cancer risk [J ] . Cancer Res , 2022 , 82 ( 11 ): 2084 - 2096 . DOI: 10.1158/0008-5472.CAN-21-4367 http://doi.org/10.1158/0008-5472.CAN-21-4367

OZTURK H , CINGOZ H , TUFAN T R , et al . ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer [J ] . Dev Cell , 2022 , 57 ( 11 ): 1331 - 1346.e9 . DOI: 10.1016/j.devcel.2022.04.014 http://doi.org/10.1016/j.devcel.2022.04.014

HUANG H , PAN R N , ZHAO Y , et al . L3MBTL2-mediated CGA transcriptional suppression promotes pancreatic cancer progression through modulating autophagy [J ] . iScience , 2022 , 25 ( 5 ): 104249 . DOI: 10.1016/j.isci.2022.104249 http://doi.org/10.1016/j.isci.2022.104249 https://linkinghub.elsevier.com/retrieve/pii/S2589004222005193 https://linkinghub.elsevier.com/retrieve/pii/S2589004222005193

NI Q Z , ZHU B , JI Y , et al . PPDPF promotes the development of mutant KRAS -driven pancreatic ductal adenocarcinoma by regulating the GEF activity of SOS1 [J ] . Adv Sci (Weinh) , 2022 : e2202448 .

DE ANDRÉS M P , JACKSON R J , FELIPE I , et al . GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma [J ] . Gut , 2022 : gutjnl-gu2021-325803.

HE D , FENG H J , SUNDBERG B , et al . Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis [J ] . Mol Cell , 2022 , 82 ( 16 ): 3045 - 3060.e11 . DOI: 10.1016/j.molcel.2022.06.005 http://doi.org/10.1016/j.molcel.2022.06.005

DOFFO J , BAMOPOULOS S A , KÖSE H , et al . NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer [J ] . Proc Natl Acad Sci U S A , 2022 , 119 ( 9 ): e2105691119.

CHENG R J , LI F Y , ZHANG M L , et al . A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers [J ] . Cell Res , 2022 . [Online ahead of print ]

MARUI S , NISHIKAWA Y , SHIOKAWA M , et al . Context-dependent roles of Hes1 in the adult pancreas and pancreatic tumor formation [J ] . Gastroenterology , 2022 , 163 ( 6 ): 1613 - 1629.e12 . DOI: 10.1053/j.gastro.2022.08.048 http://doi.org/10.1053/j.gastro.2022.08.048 https://linkinghub.elsevier.com/retrieve/pii/S0016508522010307 https://linkinghub.elsevier.com/retrieve/pii/S0016508522010307

FAN X Y , LU P , WANG H W , et al . Integrated single-cell multiomics analysis reveals novel candidate markers for prognosis in human pancreatic ductal adenocarcinoma [J ] . Cell Discov , 2022 , 8 ( 1 ): 13 . DOI: 10.1038/s41421-021-00366-y http://doi.org/10.1038/s41421-021-00366-y

SHI X H , LI Y G , YUAN Q Y , et al . Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity [J ] . Nat Commun , 2022 , 13 ( 1 ): 2169 . DOI: 10.1038/s41467-022-29857-6 http://doi.org/10.1038/s41467-022-29857-6

ZHU Q , ZHOU H , WU L M , et al . O-GlcNAcylation promotes pancreatic tumor growth by regulating malate dehydrogenase 1 [J ] . Nat Chem Biol , 2022 , 18 ( 10 ): 1087 - 1095 . DOI: 10.1038/s41589-022-01085-5 http://doi.org/10.1038/s41589-022-01085-5

LIU Y , DEGUCHI Y , WEI D Y , et al . Rapid acceleration of KRAS -mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ [J ] . Nat Commun , 2022 , 13 ( 1 ): 2665 . DOI: 10.1038/s41467-022-30392-7 http://doi.org/10.1038/s41467-022-30392-7 https://doi.org/10.1038/s41467-022-30392-7 https://doi.org/10.1038/s41467-022-30392-7

KONG W J , LIU Z S , SUN M N , et al . Synergistic autophagy blockade and VDR signaling activation enhance stellate cell reprogramming in pancreatic ductal adenocarcinoma [J ] . Cancer Lett , 2022 , 539 : 215718 . DOI: 10.1016/j.canlet.2022.215718 http://doi.org/10.1016/j.canlet.2022.215718 https://linkinghub.elsevier.com/retrieve/pii/S0304383522002026 https://linkinghub.elsevier.com/retrieve/pii/S0304383522002026

GRECO B , MALACARNE V , DE GIRARDI F , et al . Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies [J ] . Sci Transl Med , 2022 , 14 ( 628 ): eabg3072 . DOI: 10.1126/scitranslmed.abg3072 http://doi.org/10.1126/scitranslmed.abg3072 https://www.science.org/doi/10.1126/scitranslmed.abg3072 https://www.science.org/doi/10.1126/scitranslmed.abg3072

WANG Z K , MORESCO P , YAN R , et al . Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack [J ] . Proc Natl Acad Sci USA , 2022 , 119 ( 4 ): e2119463119.

MI H Y , SIVAGNANAM S , BETTS C B , et al . Quantitative spatial profiling of immune populations in pancreatic ductal adenocarcinoma reveals tumor microenvironment heterogeneity and prognostic biomarkers [J ] . Cancer Res , 2022 , 82 ( 23 ): 4359 - 4372 . DOI: 10.1158/0008-5472.CAN-22-1190 http://doi.org/10.1158/0008-5472.CAN-22-1190 https://aacrjournals.org/cancerres/article/82/23/4359/710697/Quantitative-Spatial-Profiling-of-Immune https://aacrjournals.org/cancerres/article/82/23/4359/710697/Quantitative-Spatial-Profiling-of-Immune

ZHOU D C , JAYASINGHE R G , CHEN S Q , et al . Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer [J ] . Nat Genet , 2022 , 54 ( 9 ): 1390 - 1405 . DOI: 10.1038/s41588-022-01157-1 http://doi.org/10.1038/s41588-022-01157-1

HUANG H C , WANG Z N , ZHANG Y Q , et al . Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer [J ] . Cancer Cell , 2022 , 40 ( 6 ): 656 - 673.e7 . DOI: 10.1016/j.ccell.2022.04.011 http://doi.org/10.1016/j.ccell.2022.04.011 https://linkinghub.elsevier.com/retrieve/pii/S1535610822001738 https://linkinghub.elsevier.com/retrieve/pii/S1535610822001738

KARTAL E , SCHMIDT T S B , MOLINA-MONTES E , et al . A faecal microbiota signature with high specificity for pancreatic cancer [J ] . Gut , 2022 , 71 ( 7 ): 1359 - 1372 . DOI: 10.1136/gutjnl-2021-324755 http://doi.org/10.1136/gutjnl-2021-324755

NAGATA N , NISHIJIMA S , KOJIMA Y , et al . Metagenomic identification of microbial signatures predicting pancreatic cancer from a multinational study [J ] . Gastroenterology , 2022 , 163 ( 1 ): 222 - 238 . DOI: 10.1053/j.gastro.2022.03.054 http://doi.org/10.1053/j.gastro.2022.03.054

GHADDAR B , BISWAS A , HARRIS C , et al . Tumor microbiome links cellular programs and immunity in pancreatic cancer [J ] . Cancer Cell , 2022 , 40 ( 10 ): 1240 - 1253.e5 . DOI: 10.1016/j.ccell.2022.09.009 http://doi.org/10.1016/j.ccell.2022.09.009

SU H , YANG F , FU R , et al . Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome [J ] . Nature , 2022 , 610 ( 7931 ): 366 - 372 . DOI: 10.1038/s41586-022-05169-z http://doi.org/10.1038/s41586-022-05169-z https://doi.org/10.1038/s41586-022-05169-z https://doi.org/10.1038/s41586-022-05169-z

HALBROOK C J , THURSTON G , BOYER S , et al . Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells [J ] . Nat Cancer , 2022 , 3 ( 11 ): 1386 - 1403 . DOI: 10.1038/s43018-022-00463-1 http://doi.org/10.1038/s43018-022-00463-1 https://doi.org/10.1038/s43018-022-00463-1 https://doi.org/10.1038/s43018-022-00463-1

GUBBALA V B , JYTOSANA N , TRINH V Q , et al . Eicosanoids in the pancreatic tumor microenvironment-a multicellular, multifaceted progression [J ] . Gastro Hep Adv , 2022 , 1 ( 4 ): 682 - 697 .

KIM P K , HALBROOK C J , KERK S A , et al . Hyaluronic acid fuels pancreatic cancer cell growth [J ] . Elife , 2021 , 10 : e62645 . DOI: 10.7554/eLife.62645 http://doi.org/10.7554/eLife.62645 https://elifesciences.org/articles/62645 https://elifesciences.org/articles/62645

BAI J R , LIU T , TU B , et al . Autophagy loss impedes cancer-associated fibroblast activation via downregulating proline biosynthesis [J ] . Autophagy , 2022 : 1 - 12 .

FALCOMATÀ C , BÄRTHEL S , WIDHOLZ S A , et al . Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment [J ] . Nat Cancer , 2022 , 3 ( 3 ): 318 - 336 . DOI: 10.1038/s43018-021-00326-1 http://doi.org/10.1038/s43018-021-00326-1 https://doi.org/10.1038/s43018-021-00326-1 https://doi.org/10.1038/s43018-021-00326-1

GU J Y , HUANG W J , WANG X X , et al . Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemCitabine resistance in pancreatic cancer [J ] . Mol Cancer , 2022 , 21 ( 1 ): 112 . DOI: 10.1186/s12943-022-01587-9 http://doi.org/10.1186/s12943-022-01587-9

LIU J J , JING W H , WANG T Y , et al . Functional metabolomics revealed the dual-activation of cAMP-AMP axis is a novel therapeutic target of pancreatic cancer [J ] . Pharmacol Res , 2022 , 187 : 106554 . DOI: 10.1016/j.phrs.2022.106554 http://doi.org/10.1016/j.phrs.2022.106554 https://linkinghub.elsevier.com/retrieve/pii/S104366182200500X https://linkinghub.elsevier.com/retrieve/pii/S104366182200500X

ZENG X Y , ZHAO F , CUI G F , et al . METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma [J ] . Nat Cancer , 2022 , 3 ( 9 ): 1088 - 1104 . DOI: 10.1038/s43018-022-00429-3 http://doi.org/10.1038/s43018-022-00429-3 https://doi.org/10.1038/s43018-022-00429-3 https://doi.org/10.1038/s43018-022-00429-3

VAZIRI-GOHAR A , CASSEL J , MOHAMMED F S , et al . Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors [J ] . Nat Cancer , 2022 , 3 ( 7 ): 852 - 865 . DOI: 10.1038/s43018-022-00393-y http://doi.org/10.1038/s43018-022-00393-y https://doi.org/10.1038/s43018-022-00393-y https://doi.org/10.1038/s43018-022-00393-y

WANG P Y , ZHANG T , WANG X J , et al . Aberrant human ClpP activation disturbs mitochondrial proteome homeostasis to suppress pancreatic ductal adenocarcinoma [J ] . Cell Chem Biol , 2022 , 29 ( 9 ): 1396 - 1408.e8 . DOI: 10.1016/j.chembiol.2022.07.002 http://doi.org/10.1016/j.chembiol.2022.07.002 https://linkinghub.elsevier.com/retrieve/pii/S2451945622002458 https://linkinghub.elsevier.com/retrieve/pii/S2451945622002458

LI J H , LAMA R , GALSTER S L , et al . Small-molecule MMRi62 induces ferroptosis and inhibits metastasis in pancreatic cancer via degradation of ferritin heavy chain and mutant p53 [J ] . Mol Cancer Ther , 2022 , 21 ( 4 ): 535 - 545 . DOI: 10.1158/1535-7163.MCT-21-0728 http://doi.org/10.1158/1535-7163.MCT-21-0728 https://aacrjournals.org/mct/article/21/4/535/689573/Small-Molecule-MMRi62-Induces-Ferroptosis-and https://aacrjournals.org/mct/article/21/4/535/689573/Small-Molecule-MMRi62-Induces-Ferroptosis-and

WENG N N , QIN S Y , LIU J Y , et al . Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma [J ] . Acta Pharm Sin B , 2022 , 12 ( 7 ): 3085 - 3102 . DOI: 10.1016/j.apsb.2022.01.018 http://doi.org/10.1016/j.apsb.2022.01.018

DA SILVA L , JIANG J M , PERKINS C , et al . Pharmacological inhibition and reversal of pancreatic acinar ductal metaplasia [J ] . Cell Death Discov , 2022 , 8 ( 1 ): 378 . DOI: 10.1038/s41420-022-01165-4 http://doi.org/10.1038/s41420-022-01165-4

LAN L X , EVAN T , LI H F , et al . GREM1 is required to maintain cellular heterogeneity in pancreatic cancer [J ] . Nature , 2022 , 607 ( 7917 ): 163 - 168 . DOI: 10.1038/s41586-022-04888-7 http://doi.org/10.1038/s41586-022-04888-7 https://doi.org/10.1038/s41586-022-04888-7 https://doi.org/10.1038/s41586-022-04888-7

YUAN F , SUN M N , LIU Z S , et al . Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer [J ] . Theranostics , 2022 , 12 ( 3 ): 1061 - 1073 . DOI: 10.7150/thno.65299 http://doi.org/10.7150/thno.65299

CHEN Q J , WANG Q B , WANG Y , et al . Penetrating micelle for reversing immunosuppression and drug resistance in pancreatic cancer treatment [J ] . Small , 2022 , 18 ( 18 ): e2107712 .

TIBILETTI M G , CARNEVALI I , PENSOTTI V , et al . OncoPan®: an NGS-based screening methodology to identify molecular markers for therapy and risk assessment in pancreatic ductal adenocarcinoma [J ] . Biomedicines , 2022 , 10 ( 5 ): 1208 . DOI: 10.3390/biomedicines10051208 http://doi.org/10.3390/biomedicines10051208 https://www.mdpi.com/2227-9059/10/5/1208 https://www.mdpi.com/2227-9059/10/5/1208

KHAN S , LUCK H , WINER S , et al . Emerging concepts in intestinal immune control of obesity-related metabolic disease [J ] . Nat Commun , 2021 , 12 ( 1 ): 2598 . DOI: 10.1038/s41467-021-22727-7 http://doi.org/10.1038/s41467-021-22727-7

PREVENTIVE SERVICES TASK FORCE U S , OWENS D K , DAVIDSON K W , et al . Screening for pancreatic cancer: US preventive services task force reaffirmation recommendation statement [J ] . JAMA , 2019 , 322 ( 5 ): 438 - 444 . DOI: 10.1001/jama.2019.10232 http://doi.org/10.1001/jama.2019.10232

GOGGINS M , OVERBEEK K A , BRAND R , et al . Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium [J ] . Gut , 2020 , 69 ( 1 ): 7 - 17 . DOI: 10.1136/gutjnl-2019-319352 http://doi.org/10.1136/gutjnl-2019-319352

HUANG C C , SIMEONE D M , LUK L , et al . Standardization of MRI screening and reporting in individuals with elevated risk of pancreatic ductal adenocarcinoma: consensus statement of the PRECEDE consortium [J ] . AJR Am J Roentgenol , 2022 , 219 ( 6 ): 903 - 914 . DOI: 10.2214/AJR.22.27859 http://doi.org/10.2214/AJR.22.27859 https://www.ajronline.org/doi/10.2214/AJR.22.27859 https://www.ajronline.org/doi/10.2214/AJR.22.27859

OVERBEEK K A , LEVINK I J M , KOOPMANN B D M , et al . Long-term yield of pancreatic cancer surveillance in high-risk individuals [J ] . Gut , 2022 , 71 ( 6 ): 1152 - 1160 . DOI: 10.1136/gutjnl-2020-323611 http://doi.org/10.1136/gutjnl-2020-323611 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-323611 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-323611

QURESHI T A , JAVED S , SARMADI T , et al . Artificial intelligence and imaging for risk prediction of pancreatic cancer: a narrative review [J ] . Chin Clin Oncol , 2022 , 11 ( 1 ): 1 . DOI: 10.21037/cco-21-117 http://doi.org/10.21037/cco-21-117

JAVED S , QURESHI T A , GADDAM S , et al . Risk prediction of pancreatic cancer using AI analysis of pancreatic subregions in computed tomography images [J ] . Front Oncol , 2022 , 12 : 1007990 . DOI: 10.3389/fonc.2022.1007990 http://doi.org/10.3389/fonc.2022.1007990 https://www.frontiersin.org/articles/10.3389/fonc.2022.1007990/full https://www.frontiersin.org/articles/10.3389/fonc.2022.1007990/full

AHMAD QURESHI T , GADDAM S , WACHSMAN A M , et al . Predicting pancreatic ductal adenocarcinoma using artificial intelligence analysis of pre-diagnostic computed tomography images [J ] . Cancer Biomark , 2022 , 33 ( 2 ): 211 - 217 . DOI: 10.3233/CBM-210273 http://doi.org/10.3233/CBM-210273

LEVINK I J M , KLATTE D C F , HANNA-SAWIRES R G , et al . Longitudinal changes of serum protein N-glycan levels for earlier detection of pancreatic cancer in high-risk individuals [J ] . Pancreatology , 2022 , 22 ( 4 ): 497 - 506 . DOI: 10.1016/j.pan.2022.03.021 http://doi.org/10.1016/j.pan.2022.03.021 https://linkinghub.elsevier.com/retrieve/pii/S1424390322001351 https://linkinghub.elsevier.com/retrieve/pii/S1424390322001351

DA PAIXÃO V F , SOSA O J , DA SILVA PELLEGRINA D V , et al . Annotation and functional characterization of long noncoding RNAs deregulated in pancreatic adenocarcinoma [J ] . Cell Oncol , 2022 , 45 ( 3 ): 479 - 504 . DOI: 10.1007/s13402-022-00678-5 http://doi.org/10.1007/s13402-022-00678-5 https://doi.org/10.1007/s13402-022-00678-5 https://doi.org/10.1007/s13402-022-00678-5

KANDIMALLA R , SHIMURA T , MALLIK S , et al . Identification of serum miRNA signature and establishment of a nomogram for risk stratification in patients with pancreatic ductal adenocarcinoma [J ] . Ann Surg , 2022 , 275 ( 1 ): e229 - e237 . DOI: 10.1097/SLA.0000000000003945 http://doi.org/10.1097/SLA.0000000000003945 https://journals.lww.com/10.1097/SLA.0000000000003945 https://journals.lww.com/10.1097/SLA.0000000000003945

KONNO M , KOSEKI J , ASAI A , et al . Distinct methylation levels of mature microRNAs in gastrointestinal cancers [J ] . Nat Commun , 2019 , 10 ( 1 ): 3888 . DOI: 10.1038/s41467-019-11826-1 http://doi.org/10.1038/s41467-019-11826-1

COUTO N , ELZANOWSKA J , MAIA J , et al . IgG + extracellular vesicles measure therapeutic response in advanced pancreatic cancer [J ] . Cells , 2022 , 11 ( 18 ): 2800 . DOI: 10.3390/cells11182800 http://doi.org/10.3390/cells11182800 https://www.mdpi.com/2073-4409/11/18/2800 https://www.mdpi.com/2073-4409/11/18/2800

BHANDARE M S , PARRAY A , CHAUDHARI V A , et al . Minimally invasive surgery for pancreatic cancer-are we there yet? A narrative review [J ] . Chin Clin Oncol , 2022 , 11 ( 1 ): 3 . DOI: 10.21037/cco-21-131 http://doi.org/10.21037/cco-21-131 https://cco.amegroups.com/article/view/89902/html https://cco.amegroups.com/article/view/89902/html

TOPAL H , AERTS R , LAENEN A , et al . Survival after minimally invasive vs open surgery for pancreatic adenocarcinoma [J ] . JAMA Netw Open , 2022 , 5 ( 12 ): e2248147 . DOI: 10.1001/jamanetworkopen.2022.48147 http://doi.org/10.1001/jamanetworkopen.2022.48147 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799856 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799856

SUTTON T L , POTTER K C , MAYO S C , et al . Complications in distal pancreatectomy versus radical antegrade modular pancreatosplenectomy: a disease risk score analysis utilizing national surgical quality improvement project data [J ] . World J Surg , 2022 , 46 ( 7 ): 1768 - 1775 . DOI: 10.1007/s00268-022-06545-6 http://doi.org/10.1007/s00268-022-06545-6

LI B , GUO S W , YIN X Y , et al . Risk factors of positive resection margin differ in pancreaticoduodenectomy and distal pancreatosplenectomy for pancreatic ductal adenocarcinoma undergoing upfront surgery [J ] . Asian J Surg , 2022 : S1015-S9584 ( 22 ) 01438 - 5 .

HACKERT T , KLAIBER U , HINZ U , et al . Portal vein resection in pancreatic cancer surgery: risk of thrombosis and radicality determine survival [J ] . Ann Surg , 2022 . [Online ahead of print ]

ZHOU Y P , WANG J T , ZHANG S L , et al . A CT radiomics-based risk score for preoperative estimation of intraoperative superior mesenteric-portal vein involvement in pancreatic ductal adenocarcinoma [J ] . Ann Surg Oncol , 2022 . [Online ahead of print ]

SAHLSTRÖM E , BEREZA-CARLSON P , NILSSON J , et al . Risk factors and outcomes for patients with pancreatic cancer undergoing surgical exploration without resection due to metastatic disease: a national cohort study [J ] . Hepatobiliary Pancreat Dis Int , 2022 , 21 ( 3 ): 279 - 284 . DOI: 10.1016/j.hbpd.2022.02.003 http://doi.org/10.1016/j.hbpd.2022.02.003 https://linkinghub.elsevier.com/retrieve/pii/S149938722200011X https://linkinghub.elsevier.com/retrieve/pii/S149938722200011X

ZAMBIRINIS C P , MIDYA A , CHAKRABORTY J , et al . Recurrence after resection of pancreatic cancer: can radiomics predict patients at greatest risk of liver metastasis? [J ] . Ann Surg Oncol , 2022 , 29 ( 8 ): 4962 - 4974 . DOI: 10.1245/s10434-022-11579-0 http://doi.org/10.1245/s10434-022-11579-0

ASAKURA Y , TOYAMA H , ISHIDA J , et al . Clinicopathological variables and risk factors for lung recurrence after resection of pancreatic ductal adenocarcinoma [J ] . Asian J Surg , 2023 , 46 ( 1 ): 207 - 212 . DOI: 10.1016/j.asjsur.2022.03.043 http://doi.org/10.1016/j.asjsur.2022.03.043 https://linkinghub.elsevier.com/retrieve/pii/S1015958422002858 https://linkinghub.elsevier.com/retrieve/pii/S1015958422002858

PADRÓN L J , MAURER D M , O'HARA M H , et al . Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial [J ] . Nat Med , 2022 , 28 ( 6 ): 1167 - 1177 . DOI: 10.1038/s41591-022-01829-9 http://doi.org/10.1038/s41591-022-01829-9

VERSTEIJNE E , VAN DAM J L , SUKER M , et al . Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial [J ] . J Clin Oncol , 2022 , 40 ( 11 ): 1220 - 1230 . DOI: 10.1200/JCO.21.02233 http://doi.org/10.1200/JCO.21.02233 https://ascopubs.org/doi/10.1200/JCO.21.02233 https://ascopubs.org/doi/10.1200/JCO.21.02233

YAMAGUCHI J , YOKOYAMA Y , FUJⅡ T , et al . Results of a phase Ⅱ study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01) [J ] . Ann Surg , 2022 , 275 ( 6 ): 1043 - 1049 . DOI: 10.1097/SLA.0000000000005430 http://doi.org/10.1097/SLA.0000000000005430 https://journals.lww.com/10.1097/SLA.0000000000005430 https://journals.lww.com/10.1097/SLA.0000000000005430

CANON J , REX K , SAIKI A Y , et al . The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity [J ] . Nature , 2019 , 575 ( 7781 ): 217 - 223 . DOI: 10.1038/s41586-019-1694-1 http://doi.org/10.1038/s41586-019-1694-1 https://doi.org/10.1038/s41586-019-1694-1 https://doi.org/10.1038/s41586-019-1694-1

FELL J B , FISCHER J P , BAER B R , et al . Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer [J ] . J Med Chem , 2020 , 63 ( 13 ): 6679 - 6693 . DOI: 10.1021/acs.jmedchem.9b02052 http://doi.org/10.1021/acs.jmedchem.9b02052 https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02052 https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02052

KWAN A K , PIAZZA G A , KEETON A B , et al . The path to the clinic: a comprehensive review on direct KRASG12C inhibitors [J ] . J Exp Clin Cancer Res , 2022 , 41 ( 1 ): 27 . DOI: 10.1186/s13046-021-02225-w http://doi.org/10.1186/s13046-021-02225-w https://doi.org/10.1186/s13046-021-02225-w https://doi.org/10.1186/s13046-021-02225-w

KEMP S B , CHENG N , MARKOSYAN N , et al . Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer [J ] . Cancer Discov , 2022 : CD-22 - 1066 .

MOKHTECH M , MICCIO J A , JOHUNG K , et al . Multiagent chemotherapy followed by stereotactic body radiotherapy versus conventional radiotherapy for resected pancreas cancer [J ] . Am J Clin Oncol , 2022 , 45 ( 11 ): 450 - 457 . DOI: 10.1097/COC.0000000000000947 http://doi.org/10.1097/COC.0000000000000947 https://journals.lww.com/10.1097/COC.0000000000000947 https://journals.lww.com/10.1097/COC.0000000000000947

NAFFOUJE S A , SABESAN A , KIM D W , et al . Adjuvant chemoradiotherapy in resected pancreatic ductal adenocarcinoma: where does the benefit lie? A nomogram for risk stratification and patient selection [J ] . J Gastrointest Surg , 2022 , 26 ( 2 ): 376 - 386 . DOI: 10.1007/s11605-021-05130-x http://doi.org/10.1007/s11605-021-05130-x https://doi.org/10.1007/s11605-021-05130-x https://doi.org/10.1007/s11605-021-05130-x

RUTENBERG M S , NICHOLS R C . Proton beam radiotherapy for pancreas cancer [J ] . J Gastrointest Oncol , 2020 , 11 ( 1 ): 166 - 175 . DOI: 10.21037/jgo.2019.03.02 http://doi.org/10.21037/jgo.2019.03.02

KOBEISSI J M , SIMONE C B 2nd , LIN H B , et al . Proton therapy in the management of pancreatic cancer [J ] . Cancers , 2022 , 14 ( 11 ): 2789 . DOI: 10.3390/cancers14112789 http://doi.org/10.3390/cancers14112789 https://www.mdpi.com/2072-6694/14/11/2789 https://www.mdpi.com/2072-6694/14/11/2789

NAUMANN M , CZEMPIEL T , LÖßNER A J , et al . Combined systemic drug treatment with proton therapy: investigations on patient-derived organoids [J ] . Cancers , 2022 , 14 ( 15 ): 3781 . DOI: 10.3390/cancers14153781 http://doi.org/10.3390/cancers14153781 https://www.mdpi.com/2072-6694/14/15/3781 https://www.mdpi.com/2072-6694/14/15/3781

SELVANESAN B C , CHANDRA D , QUISPE-TINTAYA W , et al . Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice [J ] . Sci Transl Med , 2022 , 14 ( 637 ): eabc1600 . DOI: 10.1126/scitranslmed.abc1600 http://doi.org/10.1126/scitranslmed.abc1600 https://www.science.org/doi/10.1126/scitranslmed.abc1600 https://www.science.org/doi/10.1126/scitranslmed.abc1600

MARIN I , BOIX O , GARCIA-GARIJO A , et al . Cellular senescence is immunogenic and promotes anti-tumor immunity [J ] . Cancer Discov , 2022 : CD-22 - 0523 .

HEWITT D B , NISSEN N , HATOUM H , et al . A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-L (HyperAcute-pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer [J ] . Ann Surg , 2022 , 275 ( 1 ): 45 - 53 . DOI: 10.1097/SLA.0000000000004669 http://doi.org/10.1097/SLA.0000000000004669 https://journals.lww.com/10.1097/SLA.0000000000004669 https://journals.lww.com/10.1097/SLA.0000000000004669

ZHANG Z W , LIU X D , ZHOU L R , et al . Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: a retrospective analysis of 302 Chinese patients [J ] . Histol Histopathol , 2022 , 37 ( 10 ): 1031 - 1040 .

MELIEF C J M . T-cell immunotherapy against mutant KRAS for pancreatic cancer [J ] . N Engl J Med , 2022 , 386 ( 22 ): 2143 - 2144 . DOI: 10.1056/NEJMe2204283 http://doi.org/10.1056/NEJMe2204283 http://www.nejm.org/doi/10.1056/NEJMe2204283 http://www.nejm.org/doi/10.1056/NEJMe2204283

浏览量

4451

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

2024年胰腺癌研究及诊疗新进展

2023年度胰腺癌研究及诊疗新进展

2021年胰腺癌研究及诊疗新进展

2020年胰腺癌研究及诊疗新进展

2018年胰腺癌研究及诊疗新进展